NCT06899906View on ClinicalTrials.gov

Efficacy and Safety of Dalbavancin As Suppressive Therapy

RecruitingOBSERVATIONAL
Enrollment

33

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

May 1, 2025

Conditions
Efficacy and Safety of DalbavancinIn Subjects Who Received SAT with DALFor Acute or Chronic Infections Between July 2019 and December 2024
Interventions
OTHER

Determine patient demographic and clinical characteristics at baseline

Description of demographic data (sex, age), comorbidities (Charlson scores), septic history, and medical management (antibiotic therapy)

Trial Locations (1)

69004

RECRUITING

HCL, France

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER